Dioxaphetyl butyrate (INN; trade names Amidalgon, Spasmoxal) is an opioid analgesic which is a diphenylacetic acid derivative, related to other open-chain opioid drugs such as dextropropoxyphene, levacetylmethadol (LAAM), lefetamine and dimenoxadol.[2][3]
It produces similar effects to other opioids, including dependence, euphoria, analgesia, sedation, constipation, dizziness and nausea.[4]
In the United States it is a Schedule I Narcotic controlled substance with an ACSCN of 9621 and a 2013 annual aggregate manufacturing quota of zero.[5]
References
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ "Dioxaphetyl butyrate". PubChem. U.S. National Library of Medicine. Retrieved 2019-06-03.
- ^ "Dioxaphetyl butyrate | C22H27NO3". ChemSpider. Retrieved 2019-06-03.
- ^ "Dioxaphetyl butyrate". drugcentral.org. Retrieved 2019-06-03.
- ^ "Misuse of Drugs Act : Legislative history · Part I Class A · Section 1(a): Explicitly named Class A substances". isomerdesign.com. Retrieved 2019-06-03.
You must be logged in to post a comment.